InterMune completes sale of Actimmune
Gross proceeds from the sale totaled $55m, while InterMune is eligible to gain a two-year royalty stream based on net sales of Actimmune. InterMune chairman, chief executive officer
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.